Recent Progress in the Development of Anticancer Agents

Sandor Eckhardt
May 2002
Current Medicinal Chemistry - Anti-Cancer Agents;May2002, Vol. 2 Issue 3, p419
Academic Journal
Cancer chemotherapy started with the discovery of the cytostatic effect of N-mustard and its derivatives more than five decades ago. This observation opened the way for the synthesis of various alkylating agents, antimetabolites and antimitotics expliciting antitumour activity against several human malignancies. The considerable toxicity of these drugs however, limited their application and only hormone-active products were relatively well tolerated. Besides, the majority of human malignant tumours proved to be chemoresistant. Consequently, there was still an urgent need for finding less toxic compounds possessing broader antitumour spectrum. Therefore, it became obvious that better understanding of the cellular metabolism - due to revolution in molecular biology - yielded new targets for cancer chemotherapeutic agents. Key enzymes active in signal transduction pathways could be blocked by new substances. Cell cycle control could be influenced by apoptosis inducers. Mitotic division could be inhibited by antitubulin agents. Multidrug resistance (MDR) could be modified by revertants. New concepts also emerged: a) chemoprevention, which is based on the principle, that since carcinogenesis is a genetically determined, progressive multistep process it can timely be reconverted into the direction of normal cellular metabolism by redifferentiating agents b) antimetastatic therapy: originally performed postoperatively as an adjuvant therapy nowadays before surgical intervention, in order to block vascular dissemination of tumor cells (neoadjuvant therapy) c) antiangiogenic therapy: substances capable to hinder the vessel production essential for the development of metastasis d) antitelomerase molecules inhibiting the immortal division capacity of DNA in malignant cells. All these new research approaches necessitate to review the existing drugs which are in clinical use or are investigational agents against human malignancies.


Related Articles

  • Celebrating novel cancer drugs. Weiss, Robin A // British Journal of Cancer;8/4/2003, Vol. 89 Issue 3, p425 

    Editorial. Focuses on cancer drug development in Great Britain. Progress and development made in cancer drugs; Development of novel means of measuring efficacy, pharmacokinetics and pharmacodynamics of the drugs in action.

  • Soil DNA libraries for anticancer drug discovery. Pettit, Robin K. // Cancer Chemotherapy & Pharmacology;Jul2004, Vol. 54 Issue 1, p1 

    Soil has the largest population of microbes of any habitat, but only about 0.3% of soil microbes are cultivable with current techniques. Cultured soil microbes have been an incredibly productive source of drugs, for example the cancer chemotherapeutics doxorubicin hydrochloride, bleomycin,...

  • palliative care.  // Annals of Oncology;2016 Supplement, Vol. 27, pvi455 

    No abstract available.

  • Vitamin D[sub 2] Analog 19-nor-1,25-Dihydroxyvitamin D[sub 2]: Antitumor Activity Against Leukemia, Myeloma, and Colon Cancer Cells. Kumagai, Takashi; O'Kelly, James; Said, Jonathan W.; Koeffler, H. Phillip // JNCI: Journal of the National Cancer Institute;6/18/2003, Vol. 95 Issue 12, p896 

    Background: 1,25-Dihydroxyvitamin D[sub 3] inhibits growth of several types of human cancer cells in vitro, but its therapeutic use is hampered because it causes hypercalcemia. 19-nor-1,25-Dihydroxyvitamin D[sub 2] (paricalcitol) is a noncalcemic vitamin D analog that is approved by the Food and...

  • Endostatin resurfaces as a potential anti-neoplastic. Moore, Amy Slugg // RN;Sep99, Vol. 62 Issue 9, p102 

    Reports that scientists at the National Cancer Institute have confirmed initial findings that endostatin could destroy malignant tumors in animals. Mechanism of action of the drug.

  • Advancing the safe and appropriate use of oral chemotherapy agents.  // American Journal of Health-System Pharmacy;5/1/2007 Supplement, Vol. 64, pS36 

    A quiz concerning oral chemotherapy is presented.

  • Targeted cancer therapies attempt to hit the bull's-eye. Miller, Mike; Miller, M // JNCI: Journal of the National Cancer Institute;12/06/2000, Vol. 92 Issue 23, p1878 

    Reports on developments in the research on targeted cancer therapies as of December 6, 2000. Barriers to the development target therapy regimens; Drugs developed for target therapy; Unusual treatments being developed as targeted therapies.

  • Keeping cancer under control.  // USA Today Magazine;Oct92, Vol. 121 Issue 2569, p5 

    Updates the status of tests on HMBA (hexamethylene bis-acetamide), a cancer-controlling drug that went to clinical trials in 1984. How it works; Promising results.

  • Bendamustime: A Viewpoint by Patrick Schöffski and Arnold Ganser. Schöffski, P.; Ganser, A. // Drugs;Mar2001, Vol. 61 Issue 5, p639 

    Discusses the use and effectiveness of bendamustine, an anticancer drug. Tolerability; Effectivity of the drug to first- and second-line treatment of patients with breast cancer; Result of its clinical trials.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics